WO2013026989A2 - Liposome comprenant au moins un derive de cholesterol - Google Patents
Liposome comprenant au moins un derive de cholesterol Download PDFInfo
- Publication number
- WO2013026989A2 WO2013026989A2 PCT/FR2012/051924 FR2012051924W WO2013026989A2 WO 2013026989 A2 WO2013026989 A2 WO 2013026989A2 FR 2012051924 W FR2012051924 W FR 2012051924W WO 2013026989 A2 WO2013026989 A2 WO 2013026989A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- oxime
- represent
- cholest
- alkyl
- Prior art date
Links
- 0 CC(C(*)[C@](C)([C@@](*)CC1)[C@]1C1(C(*)(*)C(C)(*)C(C)(*)C2(*)*)O)[C@@]12O Chemical compound CC(C(*)[C@](C)([C@@](*)CC1)[C@]1C1(C(*)(*)C(C)(*)C(C)(*)C2(*)*)O)[C@@]12O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- Liposome comprising at least one cholesterol derivative.
- the present invention relates to a new dosage form of cholesterol derivatives.
- the invention relates to liposomes comprising at least one cholesterol derivative corresponding to formula (I) described below and compositions comprising said liposomes.
- cholesterol derivative may be used to designate the compounds of formula (I), or their counterparts not specifically described in the present application, and their analogues. Indeed, all these compounds of formulas I have in common the skeleton cholesterol.
- the invention relates to liposomes comprising at least one compound corresponding to the following formula (I)
- R 2 may represent a hydrogen atom or an alkyl group Ci-C 6 cycloalkyl, C 3 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkyl, aryl, heterocycle, or halogen atom or a group -CN, -CF 3 , -NO 2 , -OR a , -SR a , -SO 2 R a , -NR a R b , -C (O) -R a , -OC (O) R a , -OC (O) NR a R b , -C (O) OR a , -C (O) NR a R b , wherein
- R a and R b may be chosen from a hydrogen atom or a CC 6 alkyl group, a C 2 -C 6 alkenyl group, a cycloalkyl group; C 3 -C 6 , an aryl group, a heterocyclic group or
- R a and R b together can form a hydrocarbon chain, linear or branched, having from 2 to 6 carbon atoms, optionally comprising one or more double bonds and / or optionally interrupted by one or more atom (s) of oxygen, sulfur or nitrogen, or
- R a and R b taken together with the nitrogen to which they are attached may form a C 3 -C 6 heterocyl, said heterocycle may comprise one or more double bonds and / or one or more d atom (s) oxygen, sulfur or nitrogen;
- R 3 may represent a hydrogen atom or a C 1 -C 6 alkyl group, or
- R 4 may represent a hydrogen atom or a C 1 -C 6 alkyl group, or a hydroxyamino group (-NH 2 -OH); or
- R 3 and R 4 taken together may form an additional carbon-carbon bond between the carbon atoms to which they are attached, or a C 3 -C 6 cycloalkyl group;
- R 5 mayirrirun hydrogen atom or an alkyl group Ci-C 6 cycloalkyl, C 3 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkyl, aryl, or -CN, -OR a , -SR a , -SO 2 R a , -NR a R b , -C (O) -R a , -OC (O) R a , -OC (O) NR a R b , R a and R b being as defined above, or a hydroxyamino group (-NH 2 -OH);
- R 8 may represent a group selected from a C 4 -C 4 alkyl group
- Ru may represent a C 4 -C 6 alkyl group; 2 or a C 4 -C 12 alkenyl group, especially a C 5 -C 10 alkyl group, preferentially the following G 7 grouping
- Y may represent an oxygen atom or a group -NR a with R a being as previously described, and
- R15 may be an alkyl -C 6 cycloalkyl, C 3 -C 6 alkyl, aryl, heterocycle, -C (0) -C 6 -C, -C (0) -cycloalkyl, C3-C6 alkyl, -C (0 ) -aryl, -C (O) -heterocycle, in particular a group represented by one of the formulas (III) or (IV)
- R 6 may represent a hydrogen atom or a halogen atom or a hydroxyl group, preferably a hydrogen atom;
- R 7 may represent a hydrogen atom, or a group -OR a , R a being as defined above, preferably a hydrogen atom;
- R 1 can represent a hydrogen atom or a group -CH 3, -CH 2 -CN, -CH 2 -OR a , -CH 2 -SR a , -CH 2 -SeR a , -C (O) -R a , -C (O) OR a , -O-C (O) NR a R b , -C (O) NR a R b , R a and R b being as defined above,
- R a and R b being as previously defined and
- n can represent an equal integer that can take any of the values from 0 to 4, or
- m can represent an integer that can take any of the values from 1 to 8.
- Q may represent an oxygen atom or a group -NR a in which R a is as defined above and
- R c can represent
- R 9 may represent a hydrogen atom, a C 1 -C 6 alkyl group or a halogen atom;
- Rg and Ru taken together may form an additional carbon-carbon bond between the carbon atoms to which they are attached, or a C 3 -C 6 cycloalkyl group;
- R 0 may represent a hydrogen atom, a halogen atom or a group -OR a , -SR a , -CN, -NR a R b , -R a and -R b being as defined above;
- Ru may represent a hydrogen atom, or an alkyl group -C 6 cycloalkyl, C 3 -C 6 aryl or a halogen atom;
- R-I2 may represent a hydrogen atom or an alkyl group Ci-C 6 or a halogen atom or a -CN, -OR a, -SR a, -SeR a, -C (0) -R a , -C (O) OR a , -NR a R b , -OC (O) NR a R b , -R a and -R b being as defined above; or
- R13 may represent a hydrogen atom or an alkyl group Ci-C 6, or a halogen atom or a -CN, -CF 3, -N0 2, -OR a, -SR a, -S0 2 R a , -NR a R b , -C (O) -R a , -OC (O) R a , -OC (O) NR a R b , -C (O) OR a , -C (O) NR a R b or together with Z a carbon-carbon bond
- Z can represent a hydrogen atom, a hydroxyl group, a hydroxyamino group or together with R 13 a carbon-carbon bond and R 1 may represent a hydrogen atom or a group -CH 3 , -CH 2 -CN, -CH 2 -SR a , -CH 2 -SeR a or a group corresponding to formula (VII) or (VIII) next :
- + W may represent an oxygen atom or a group -NR a in which R a is as defined above or a spacer arm consisting of an optionally substituted linear or branched hydrocarbon chain containing from 2 to 20 carbon atoms and further comprising at least one heteroatom;
- esters and their addition salts with pharmaceutically acceptable acids are generally not directly active in themselves but are prodrugs for the corresponding hydroxylated analogs.
- esters which are metabolized in the human body, lead to the active compounds.
- esters are also the subject of the present invention. Esters which introduce chemical functionalities such as sulphates, phosphates, acids and basic chains which increase aqueous solubility and bioavailability can be mentioned.
- Esters of compounds having a basic function such as dialkylglycine analogs with alkyls of 1 to 4 carbon atoms and most particularly dimethylglycine and diethylglycine are preferred. and also methylpiperazine.
- Fatty acid esters or polyethylene glycol chain esters which increase the affinity for lipophilic phases may be mentioned. Saturated fatty acid chains of 3 to 18 carbons are preferred.
- C x -C y alkyl refers to a linear or branched hydrocarbon radical comprising from x to y carbon atoms.
- the invention according to the listed cases covers linear or branched hydrocarbon radicals, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl.
- Alkyl groups CrC 6 are preferred.
- the alkyl groups may optionally be substituted by an aryl group as defined below, in which case it is called an arylalkyl group.
- arylalkyl groups include benzyl and phenethyl.
- the alkyl groups may be substituted one or more times with one or more substituents, which may be identical or different, chosen independently from a halogen atom or a group -CN, -CF 3 , -C (O) -R a , -C (O) OR a , -C (O) NR a R b , -O-C (O) NR a R b , -NR a R b , -OR a , -SR b , the groups R a and R b may be as described above.
- C x -C y alkenyl refers to a linear or branched or cyclic hydrocarbon radical, comprising one or more double bonds, having from x to y carbon atoms.
- the alkenyl groups may be substituted one or more times with one or more substituents, which may be identical or different, chosen independently from a halogen atom or a group -CN, -CF 3) -C (O) -R a , -C (O) OR a , -C (O) NR a R b , -O-C (O) NR a R b , -NR a R b , -OR a , -SR b , the groups R a , R b may be as previously described;
- C x -C y cycloalkyl refers to a saturated or partially unsaturated cyclic hydrocarbon radical having from x to y carbon atoms.
- Cycloalkyl groups include, in particular, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl substituents.
- the cycloalkyl groups may be substituted one or more times with one or more substituents, which may be identical or different, chosen independently from a halogen atom or a group -CN, -CF 3 , -C (O) -R a , -C (O) OR a , -C (O) NR a R b , -O-C (O) NR a R b , -NR a R b , -OR a , -SR a , the group R a , R b may be as previously described;
- alkynyl, C x -C y refers to a hydrocarbon radical straight, branched, including at least one triple bond, having from x to y carbon atoms.
- the alkynyl groups include, in particular, the ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1-heptynyl, 2-heptynyl, 1-octynyl and 2-octynyl substituents.
- the alkynyl groups may be substituted one or more times with one or more substituents, which may be identical or different, chosen independently from a halogen atom or a group -CN, -CF 3 , -C (O) -R a , -C (O) OR a , -C (O) NR a R b , -O-C (O) NR a R b , -NR a R b , -OR a , -SR a , the groups R a , R b may be as previously described;
- C x -C y aryl refers to an aromatic hydrocarbon radical having x to y carbon atoms.
- aromatic hydrocarbon radicals having 6 carbon atoms are preferred.
- the aryl groups include in particular the phenyl, naphthyl and biphenyl radicals.
- the aryl groups may be substituted one or more times with one or more substituents, which may be identical or different, chosen independently from a halogen atom or an alkyl group, -CN, -CF 3 , -N 3 , -NO 2 , -C (O) OR a , -C (O) -R a , -C (O) NR a R b , -O-C (O) NR a R b , -NR a R b , -OR a -SR a , the groups R a , R b may be as previously described;
- C x -C y heterocycle refers to an optionally substituted mono- or polycyclic, saturated, unsaturated or aromatic radical, which can have from one to four carbon atoms and comprising one or more heteroatoms.
- the heteroatoms are selected from oxygen, sulfur and nitrogen.
- heterocycle examples include furyl, thienyl, pyrrole, imidazole, isothiazole, thiazole, isoxazole, oxazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, indazole, quinoline, isoquinoline, phthalazine, quinazoline, pyrrolidine, imidazolidine, pyrrazolidine, piperidine, piperazine, morpholine, thiazolidine or phthalimide. benzimidazole.
- the heterocyl groups may be substituted one or several times by one or more substituents the same or different selected (s) independently selected from a halogen atom or an alkyl group, -CN, -CF 3, -N 3l -N0 2> -C (0) OR a, - C (O) -R a , -C (O) NR a R b , -O-C (O) NR a R b , -NR a R b , -OR a , -SR a , the groups R a , R b may be as previously described;
- halogen refers to a chlorine, bromine, fluorine and iodine atom.
- the halogen will be a fluorine atom.
- the compounds of formula (I) are known and are particularly described in international applications WO 2006/027454 of March 13, 2006, WO 2007/101925 of September 13, 2007, WO 2009/044011 of September 09, 2009, WO 2010/076418 of 08 July 2010, WO 2004/082581 of September 30, 2004, WO 2007/080270 of July 19, 2007, WO2007 / 118967 of October 25, 2007, WO 008/142237 of November 27, 2008, WO 2009/044010 of April 09, 2009, WO 2009 / 092892 of July 30, 2009 and WO 2010/012904 of February 4, 2010.
- cholesteryl derivatives especially those of formula (I), especially 3-hydroxy-3,5-seco-4-norcholestan-5-oxime
- One and the oxime of cholest-4-en-3-one are useful as medicaments and particularly have remarkable cytoprotective properties, particularly neuroprotective, cardioprotective and hepatoprotective properties.
- compositions comprising active ingredients having a low aqueous solubility
- surfactants for the formation of emulsions, colloids such as micelles or liposomes which solubilize the drug and increase its solubility in an aqueous medium.
- these emulsions and in particular the micellar suspensions are not physically or even chemically stable. For example, if the composition comes into contact with blood or plasma, the solubilizing system can lose these properties by no longer retaining the active ingredient.
- surfactant cremophore, tween, etc.
- particulate structures are a source of activation of the complement system of higher organisms and the triggering of reactogenicity reactions that can be fatal.
- the invention aims among other things to overcome these problems and difficulties.
- the Applicant has, surprisingly, discovered that the cholesterol derivatives, particularly those described in the international applications cited above, advantageously those corresponding to formula (I), have a very good affinity with liposomes, which also makes it possible to to prepare compositions, particularly pharmaceutical compositions, which are stable for several months physically and chemically and concentrated in active principle.
- these compositions placed in contact with a biological medium such as blood are chemically stable and the active agent retains all its properties.
- compositions once administered surprisingly have a very low reactogenicity.
- the liposomes according to the invention have a remanence in biological fluids, particularly in the blood, which is prolonged.
- the invention lies in the fact that the liposomes according to the invention allow a much greater solubilization of the compounds of formula (I) and while having a very low reactogenicity.
- compounds of formula (I) when included in the liposomes according to the invention can be formulated in pharmaceutical compositions in contact with aqueous media much more easily than if they are in another form.
- the liposomes consist of at least one lipid bilayer membrane enclosing an aqueous internal compartment. They are known as system effective formulations for transporting therapeutic agents, drugs, or active ingredients within the aqueous space present inside the vesicle (soluble agents in aqueous medium) or included in the lipid bilayer (insoluble agents in aqueous medium) . They can be characterized by the type of membrane and their size.
- the unilamellar vesicles consist of a single bilayer membrane.
- Multilamellar vesicles (MLVs) contain at least two lipid bilayer membranes defining several closed aqueous compartments. The membranes are organized concentrically so that the different membranes are separated by an aqueous compartment.
- Small unilamellar vesicles can have a diameter generally between 20 and 100 nm.
- Large unilamellar vesicles LUV: large unilamellarvesicle
- MLV multilamellar vesicle
- LUV large unilamellarvesicle
- MLV multilamellarvesicle
- Liposomes it is possible to refer to Gregory Gregoriadis (Liposome Technology: Liposome Preparation And Related
- PEGylation which consists of the introduction of PEG (Poly Ethylene Glycol) chains often grafted on phospholipids or cholesterol.
- PEG Poly Ethylene Glycol
- sterols such as cholesterol into the lipid bilayer improves the stabilization of liposomes.
- US Patent 6,143,321 describes liposomes whose active ingredient is embedded or adsorbed in the lipid bilayer using a surfactant.
- An improvement in the physical and chemical stability of the liposomes according to the invention represents one of the great advantages of the invention since it makes it possible to envisage the preparation of low volume compositions comprising a large quantity of active ingredient, which could make it possible to consider, especially in the case of pharmaceutical compositions, to deliver to patients only few doses, or even a single dose, of drugs which can help to limit or annihilate the problems of hypersensitization (reactogenicity) that could cause the administration of several doses of drug solubilized using liposomes.
- the active ingredient that can be included in the liposomes according to the invention is sufficient on its own to confer improved stability to the liposomes without the addition of additional sterol.
- weakly reactogenic pharmaceutical composition is meant in the present text that the group having received the composition induces a level of reactogenicity similar to that induced in the control group of the test having received only the buffer of this composition.
- a bolus administration corresponds to the administration of a quantity necessary to obtain the expected concentration in the blood, the lymph, the cerebrospinal fluid or any biological site targeted for reasons therapeutic or diagnostic in a short time between 1 second and 10 minutes, preferably in less than 5 minutes, very preferably in less than 2 minutes.
- a weakly reactogenic composition increases the level of the complement by a maximum of three times compared to the basal level measured on the serum of the individual.
- the level of C terminal complex (SC56-9) can be measured by an immunoassay kit such as that of Quibel Corporation "SC56-9 plus Elisa” kits.
- compositions preferably pharmaceutical, having the following advantages:
- the subject of the invention is liposomes comprising at least one of the compounds corresponding to formula (I) or a mixture of compounds corresponding to formula (I).
- the subject of the invention is also a composition, particularly a pharmaceutical composition comprising liposomes comprising at least one of the compounds corresponding to formula (I) or a mixture of compounds corresponding to formula (I).
- the invention is directed to any known type of liposome provided that it is used to encapsulate an active agent, particularly a compound of formula (I)
- the final liposomal solution may comprise at least:
- cryoprotective agent optionally a cryoprotective agent.
- the compound of formula (I) included in the liposomes according to the invention may be chosen from
- the compound of formula (I) included in the liposomes according to the invention may be chosen from the oxime of cholest-4-en-3-one, the oxime of cholestan-3-one, cholest-1,4-dien-3-one oxime, cholest-4,24-dien-3-one oxime, 3-hydroxy-3,5-oxime -seco-4-norcholestan-5-one, 4-fluoro-cholest-4-en-3-one oxime, 3-hydroxy-3-methyl-3,5-seco-4-norcholestan oxime 5-one, oxime of 3,3-methyl-3-hydroxy-3,5-seco-4-norcholestan-5-one, very preferably the oxime of cholest-4-en-3-one and 3-hydroxy-3,5-seco-4-norcholestan-5-one oxime.
- the invention also relates to liposomes for which a mixture of at least two compounds of formula (I) can be used for their constitution.
- the compound of formula (I) may be present in the liposome at physiologically effective doses.
- the compound of formula (I) may be present in the final liposomal solution in an amount ranging from 0.1 to 200 mg / ml, preferably above 1 mg / ml, even more preferentially at above 5 mg / mL, very preferably above 10 mg / mL).
- final liposomal solution is meant the liposome solution obtained after carrying out the process for obtaining the liposomes according to the invention.
- the phospholipids used may be phospholipids of natural origin, vegetable or animal, or synthetic, even more preferably natural phospholipids.
- Said phospholipids may be chosen from phosphoacylglycerols (better known under the name of glycerophospholipids), inositophosphatides, phosphosphingolipids and phosphonosphingolipids or else phosphosaccharolipids.
- the phospholipids may be chosen from phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, linoleylpalmitoylphosphatidylcholine, palmitoyloleoylphosphatidylcholine, oleoylmitoylphophatidylcholine, DHAstearoylphosphatidylcholine, phosphatidylcholine of DHA-enriched avian origin, phosphatidylinositol and DHA-phosphatidylethanolamine.
- phosphatidylserine, sphingomyelin a mixture of phospholipids of avian origin close to the composition of breast milk, a mixture of phospholipids of soy origin close to the composition of breast milk, palmitic or oleic lysophosphatidic acids, egg lysophosphatidylcholine containing more than 90% palmitic and stearic acids, soy lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylethanolamine, lysophosphatidylserine, a mixture of egg phospholipids containing phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and sphingomyelin, 1,2-dioleolyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn
- the phospholipids of natural origin and particularly the phospholipids of egg or soya, preferably egg phospholipids, are used.
- the invention also relates to liposomes for which a mixture of at least two phospholipids can be used for their constitution.
- the phospholipids may be present in the final liposomal solution in an amount ranging from 10 to 300 mg / ml, preferably between 20 and 200 mg / ml, very preferably between 50 and 150 mg / ml).
- the concentration ratio of the compound of formula (I) to that of the phospholipid can be included in the final liposomal solution between 1/100 and 70/100, preferably between 10/100. and 50/100.
- the pH stabilizing agent may be a phosphate buffer, benzoate, citrate, glutamate, lactate, ascorbate, tartrate, succinate, adipate, glycinate, malate, triethanolaminate, diethanolaminate, tromethaminate.
- a phosphate buffer is used.
- the pH stabilizing agent can allow the pH of the liposomal formulation to vary between 3 and 11, preferably between 4 and 9.
- the skilled person will easily adjust the amount of stabilizing agent to be introduced according to the invention. on the one hand, the final pH of the liposomal formulation that it wishes to obtain and as a function of the chosen buffer and its physical properties.
- the cryoprotective agent may be for example glycerol, sucrose, dextrose, trehalose, glucose, maltose, mannose, lactose, mannitol, sorbitol, glycine, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), gelatin, Palanine, lysine, polyethylene glycol, dextran, aerosil, fructose, hydroxypropyl- ⁇ -cyclodextrin.
- glycerol, sucrose and dextrose are used according to the invention.
- cryoprotective agent may be present in the liposomal formulation in an amount ranging from 0.01 to 30% in solution, preferably between 0.1 and 20%, very preferably between 1 and 10%.
- the compound of formula (I) can be combined with other active therapeutic agents.
- this active ingredient can be combined with another complementary or secondary incorporated either in said lipid lipid layer, or in the aqueous phase depending on their solubility.
- the liposome according to the present invention may be used alone or in composition in animals or humans, particularly mammals, more specifically in humans. They can be for cosmetic, pharmaceutical or veterinary use.
- composition comprising at least one liposome comprising at least one compound of formula (I).
- composition of the invention may also contain usual adjuvants in the domains considered depending on the mode of administration, such as, for example, preservatives, antioxidants, pigments and dyestuffs, thickeners, flavors, sweeteners, agents that stabilize the particles of active ingredients.
- adjuvants such as, for example, preservatives, antioxidants, pigments and dyestuffs, thickeners, flavors, sweeteners, agents that stabilize the particles of active ingredients.
- these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.0001% to 10% of the total weight of the composition. These adjuvants are introduced into the aqueous or lipophilic phase.
- the liposome or the composition comprising at least one liposome can be administered enterally, parenterally or topically, preferably parenterally.
- administration may be intravenous or intraarterial or intralymphatic, direct (syringe) or indirect (infusion or angioplasty).
- a vein In the case of a vein it may be superficial, usually on the arm (peripheral venous line) or deep (central venous line), most often on the neck (jugular vein) or under the clavicle (subclavian vein) ), subcutaneously, under the skin, frequently in the abdomen or thighs, intradermally, directly into the dermis, intramuscularly, directly into a muscle or by pulmonary inhalation.
- the administration can be made intravenously.
- the subject of the invention is also the use of the compounds of formula (I) for preparing liposomes, advantageously stable liposomes.
- the subject of the invention is also the use of the liposomes according to the invention for preparing a composition, advantageously a weakly reactogenic, cosmetic, pharmaceutical or veterinary composition.
- the invention further relates to the use of liposomes according to the invention for the transport of active principles other than the compounds of formula (I).
- EPC L- ⁇ -Phosphatidylcholine of egg
- DMPG 1,2-dimyristoylphosphatidylglycerol
- DSPE-PEG 1, 2-distearoyl-SA7-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol) -2000]
- PBS Phosphate phosphate buffer
- Intralipide® injectable lipid emulsion, generally used in parenteral nutrition, sold by the Fresenius Kabi France laboratory
- Solutol HS15® nonionic solubilizer sold by BASF.
- the liposomal formulation allows a solubility of the compounds of formula (I) in an aqueous medium greater than or equal to 8 mg / ml and at a concentration equal to or greater than a highly lipophilic medium but immiscible with an aqueous biological medium.
- a solution of lipids at 250 mg / mL is prepared by dissolving defined amounts of EPC and the compound of formula (I) in tert-butanol or a mixture of tert-butanol and absolute ethanol (v / v). This lipid solution is mixed at a certain temperature on the aqueous buffer in order to obtain a final solvent concentration of 15 to 17% and a product of formula (I) of 25 or 50 mg / ml.
- the large multilamellar vesicles are then extruded at a temperature fixed through 3 polycarbonate filters by 10 consecutive passes.
- the unencapsulated compound of formula (I) is removed on the filters.
- the solvent is removed by membrane filtration by washing with buffer in order to reach a final solvent percentage of the order of 0.4%.
- the liposome solutions with the compounds were carried out with concentrations between 3 and 15 mg / mL.
- the size of the vesicles is very homogeneous from one compound to another, of the order of 80 nm corresponding to small unilamellar vesicles.
- a 250 mg / mL lipid solution is prepared by dissolving defined amounts of phospholipids and compound 1 in a mixture of tert-butanol and absolute ethanol (v / v). This lipid solution is mixed at ambient temperature with the aqueous buffer in order to obtain a final solvent concentration of 20% and total lipids of 50 mg / ml.
- the large multilamellar vesicles are then extruded at room temperature through 3 to 5 polycarbonate filters. From 5 to 10 passages are required to generate small unilamellar vesicles of size between 70 and 90 nm.
- the solvent and the unencapsulated 3-hydroxy-3,5-seco-4-norcholestan-5-one oxime are removed by diafiltration using 10 volumes of buffer wash. Ultrafiltration is then put in place to concentrate the formulation at the final concentration.
- composition Composition (compound 1 + phospholipids of column B)
- compositions have small unilamellar vesicles of 50 to 100 nm with concentrations around 20 to 35 mg / ml, with the exception of composition 2.
- a small percentage of DSPE-PEG seems to form large unilamellar vesicles or multilamellar of 220 nm in the same range of final concentration of compound 1.
- the in vitro evaluation of the reactogenicity is performed by measuring the production of the SC5 ⁇ -9 complex after incubation in human serum. Levels of SC56-9 are measured with an ELISA kit according to the method described (QuidelCorporation SC56-9 Plus EIA kit, Ref A029).
- the solutions tested are diluted with buffer to reach a compound concentration of the compound (I) of 20 mg / ml.
- 1 volume of liposomal solution prepared in Example 3 is added to 3 volumes of serum to reach a final tested concentration of 5 mg / ml.
- the mixture is stirred vigorously and incubated for 45 minutes at 37 ° C.
- the reaction is stopped with the "stop" solution of the Elisa kit.
- a Phase 1 clinical study was performed with liposomal formulation No. 1 exemplified in Example 3 of 3-hydroxy-3,5-seco-4-norcholestan-5-one oxime.
- the formulation was administered to 54 healthy volunteers intravenously at several doses and rates according to the protocol submitted to the AFSSAPS and the committee for the protection of persons.
- This formulation showed a very good tolerance up to the maximum tested dose of 13 mg / kg at 10 mL / min and the maximum flow of 35 mL / min for the dose of 10 mg / kg and a good exposure of the product of formula (I).
- the liposome solution No. 11 exemplified in Example 3 of the 3-hydroxy-3,5-seco-4-norcholestan-5-one oxime was set at +5 and + 25 ° C and analyzed after 3, 6, 12 months. Parameters T0 3 months 6 months 12 months
- the measured parameters are stable for at least one year at 25 ° C.
- the liposomal solution can be stored for at least 1 year at 25 ° C
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/240,990 US20150056269A1 (en) | 2011-08-25 | 2012-08-22 | Liposome comprising at least one cholesterol derivative |
MX2014002228A MX2014002228A (es) | 2011-08-25 | 2012-08-22 | Liposoma que contiene al menos un derivado de colesterol. |
CN201280041297.5A CN103764122A (zh) | 2011-08-25 | 2012-08-22 | 包含至少一种胆甾醇衍生物的脂质体 |
JP2014526535A JP6162699B2 (ja) | 2011-08-25 | 2012-08-22 | 少なくとも1つのコレステロール誘導体を含むリポソーム |
EP12758576.8A EP2747750A2 (fr) | 2011-08-25 | 2012-08-22 | Liposome comprenant au moins un derive de cholesterol |
BR112014004163A BR112014004163A2 (pt) | 2011-08-25 | 2012-08-22 | lipossoma, composição, uso de pelo menos um composto de fórmula (i) e uso dos lipossomas |
CA2845691A CA2845691A1 (fr) | 2011-08-25 | 2012-08-22 | Liposome comprenant au moins un derive de cholesterol |
AU2013203682A AU2013203682B2 (en) | 2011-08-25 | 2013-04-11 | Liposome comprising at least one cholesterol derivative |
US15/184,122 US20160339041A1 (en) | 2011-08-25 | 2016-06-16 | Liposome comprising at least one cholesterol derivative |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1102594A FR2979239A1 (fr) | 2011-08-25 | 2011-08-25 | Liposome comprenant au moins un derive de cholesterol |
FR1102594 | 2011-08-25 | ||
FR1102862A FR2979240A1 (fr) | 2011-08-25 | 2011-09-21 | Liposome comprenant au moins un derive de cholesterol |
FR1102862 | 2011-09-21 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/240,990 A-371-Of-International US20150056269A1 (en) | 2011-08-25 | 2012-08-22 | Liposome comprising at least one cholesterol derivative |
AU2013203682A Division AU2013203682B2 (en) | 2011-08-25 | 2013-04-11 | Liposome comprising at least one cholesterol derivative |
US15/184,122 Division US20160339041A1 (en) | 2011-08-25 | 2016-06-16 | Liposome comprising at least one cholesterol derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013026989A2 true WO2013026989A2 (fr) | 2013-02-28 |
WO2013026989A3 WO2013026989A3 (fr) | 2013-08-08 |
Family
ID=45422200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2012/051924 WO2013026989A2 (fr) | 2011-08-25 | 2012-08-22 | Liposome comprenant au moins un derive de cholesterol |
Country Status (9)
Country | Link |
---|---|
US (2) | US20150056269A1 (fr) |
EP (1) | EP2747750A2 (fr) |
JP (2) | JP6162699B2 (fr) |
CN (1) | CN103764122A (fr) |
BR (1) | BR112014004163A2 (fr) |
CA (1) | CA2845691A1 (fr) |
FR (2) | FR2979239A1 (fr) |
MX (1) | MX2014002228A (fr) |
WO (1) | WO2013026989A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11590079B2 (en) * | 2018-01-18 | 2023-02-28 | EndoProtech, Inc. | Treating microvascular dysfunction |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143321A (en) | 1997-02-06 | 2000-11-07 | Duke University | Liposomes containing active agents |
WO2004082581A2 (fr) | 2003-03-11 | 2004-09-30 | Trophos | Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives |
WO2006027454A1 (fr) | 2004-09-07 | 2006-03-16 | Trophos | Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations |
WO2007080270A2 (fr) | 2005-12-20 | 2007-07-19 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
WO2007101925A1 (fr) | 2006-03-09 | 2007-09-13 | Trophos | Utilisation de derives du 3,5-seco-4-nor-cholestane pour l'obtention d'un medicament cytoprotecteur |
WO2007118967A1 (fr) | 2006-03-31 | 2007-10-25 | Trophos | Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur |
WO2008142237A2 (fr) | 2007-03-28 | 2008-11-27 | Fillon Technologies | Valve pour le dosage de fluides visqueux, notamment pour le dosage de peintures |
WO2009044010A2 (fr) | 2007-07-25 | 2009-04-09 | Trophos | Utilisation d'au moins un dérivé oxime de la cholest-4-èn-3-one comme antioxydants |
WO2009044011A2 (fr) | 2007-07-25 | 2009-04-09 | Trophos | Utilisation d'au moins un dérivé oxime du 3,5-seco-4-nor-cholestane comme antioxydants |
WO2009092892A2 (fr) | 2007-10-30 | 2009-07-30 | Trophos | Nouvelle composition pour traiter les effets secondaires des traitements anticancereux |
WO2010012904A2 (fr) | 2008-07-30 | 2010-02-04 | Trophos | Nouveaux dérivés de l'oxime de cholest-4-èn-3-one, compositions pharmaceutiques les renfermant, et procédé de préparation |
WO2010076418A1 (fr) | 2008-12-29 | 2010-07-08 | Trophos | Nouveaux dérivés d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procédé de préparation |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7900458L (sv) * | 1978-01-27 | 1979-07-28 | Sandoz Ag | Liposom-avgivningssystem for lekemedel |
US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
DE3542773A1 (de) * | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | Hautwirksame pharmaka mit liposomen als wirkstofftraeger |
FR2650181B1 (fr) * | 1989-07-27 | 1993-12-03 | Laboratoire Stallergenes | Procede pour combiner un melange de substances heterogenes a des liposomes |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE4432378A1 (de) * | 1994-09-12 | 1996-03-14 | Bayer Ag | Injizierbare liposomale Arzneizubereitungen |
DE69628909T2 (de) * | 1995-10-12 | 2003-12-24 | Supergen Inc | Liposomformulierung von 5-beta steroiden |
EP1037610A4 (fr) * | 1997-09-16 | 2004-07-07 | Osi Pharm Inc | Compositions a base de liposomes renfermant de la camptothecine |
GB0111279D0 (en) * | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
AR031744A1 (es) * | 2001-11-08 | 2003-10-01 | Paoli Tomas De | Proliposomas en polvo, un procedimiento para la elaboracion de dichas proliposomas en polvo, procedimiento para la preparacion de una composicion farmaceutica empleando proliposomas en polvo y aparato para ser empleado en el procedimiento de elaboracion de dichas proliposomas en polvo |
WO2006050327A2 (fr) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Formulations de liposomes lyophilises et methode associee |
BRPI0619565A2 (pt) * | 2005-12-08 | 2011-10-04 | Wyeth Corp | composições lipossÈmicas |
US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
FR2914188B1 (fr) * | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
CA2760138C (fr) * | 2009-04-27 | 2014-11-04 | Balaraman Kalyanaraman | Composes neuroprotecteurs et leur utilisation |
CN101642431B (zh) * | 2009-08-28 | 2011-02-02 | 海南永田药物研究院有限公司 | 奥扎格雷钠脂质体注射剂 |
WO2011092708A2 (fr) * | 2010-02-01 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Liposomes comprenant des médicaments amphipathiques et procédé pour leur préparation |
-
2011
- 2011-08-25 FR FR1102594A patent/FR2979239A1/fr active Pending
- 2011-09-21 FR FR1102862A patent/FR2979240A1/fr active Pending
-
2012
- 2012-08-22 EP EP12758576.8A patent/EP2747750A2/fr not_active Withdrawn
- 2012-08-22 MX MX2014002228A patent/MX2014002228A/es unknown
- 2012-08-22 US US14/240,990 patent/US20150056269A1/en not_active Abandoned
- 2012-08-22 BR BR112014004163A patent/BR112014004163A2/pt not_active Application Discontinuation
- 2012-08-22 WO PCT/FR2012/051924 patent/WO2013026989A2/fr active Application Filing
- 2012-08-22 CA CA2845691A patent/CA2845691A1/fr not_active Abandoned
- 2012-08-22 CN CN201280041297.5A patent/CN103764122A/zh active Pending
- 2012-08-22 JP JP2014526535A patent/JP6162699B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-16 US US15/184,122 patent/US20160339041A1/en not_active Abandoned
-
2017
- 2017-03-22 JP JP2017056092A patent/JP2017122119A/ja active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143321A (en) | 1997-02-06 | 2000-11-07 | Duke University | Liposomes containing active agents |
WO2004082581A2 (fr) | 2003-03-11 | 2004-09-30 | Trophos | Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives |
WO2006027454A1 (fr) | 2004-09-07 | 2006-03-16 | Trophos | Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations |
WO2007080270A2 (fr) | 2005-12-20 | 2007-07-19 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
WO2007101925A1 (fr) | 2006-03-09 | 2007-09-13 | Trophos | Utilisation de derives du 3,5-seco-4-nor-cholestane pour l'obtention d'un medicament cytoprotecteur |
WO2007118967A1 (fr) | 2006-03-31 | 2007-10-25 | Trophos | Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur |
WO2008142237A2 (fr) | 2007-03-28 | 2008-11-27 | Fillon Technologies | Valve pour le dosage de fluides visqueux, notamment pour le dosage de peintures |
WO2009044010A2 (fr) | 2007-07-25 | 2009-04-09 | Trophos | Utilisation d'au moins un dérivé oxime de la cholest-4-èn-3-one comme antioxydants |
WO2009044011A2 (fr) | 2007-07-25 | 2009-04-09 | Trophos | Utilisation d'au moins un dérivé oxime du 3,5-seco-4-nor-cholestane comme antioxydants |
WO2009092892A2 (fr) | 2007-10-30 | 2009-07-30 | Trophos | Nouvelle composition pour traiter les effets secondaires des traitements anticancereux |
WO2010012904A2 (fr) | 2008-07-30 | 2010-02-04 | Trophos | Nouveaux dérivés de l'oxime de cholest-4-èn-3-one, compositions pharmaceutiques les renfermant, et procédé de préparation |
WO2010076418A1 (fr) | 2008-12-29 | 2010-07-08 | Trophos | Nouveaux dérivés d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procédé de préparation |
Non-Patent Citations (3)
Title |
---|
BANGHAM AD.; STANDISH MM.; WATKINS JC., J. MOL. BIOL., vol. 13, 1965, pages 238 - 252 |
GREGORY GREGORIADIS: "Liposome Technology: Liposome Preparation And Related Techniques,3ème édition,", 2007 |
SZEBENI J., TOXICOLOGY, vol. 216, 2005, pages 106 |
Also Published As
Publication number | Publication date |
---|---|
WO2013026989A3 (fr) | 2013-08-08 |
US20150056269A1 (en) | 2015-02-26 |
JP2014524460A (ja) | 2014-09-22 |
MX2014002228A (es) | 2014-05-28 |
EP2747750A2 (fr) | 2014-07-02 |
FR2979239A1 (fr) | 2013-03-01 |
BR112014004163A2 (pt) | 2017-03-14 |
CA2845691A1 (fr) | 2013-02-28 |
JP6162699B2 (ja) | 2017-07-12 |
CN103764122A (zh) | 2014-04-30 |
FR2979240A1 (fr) | 2013-03-01 |
US20160339041A1 (en) | 2016-11-24 |
JP2017122119A (ja) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2681302C (fr) | Compositions proliposomales et liposimale de composes faiblement hydrosolubles | |
US6287593B2 (en) | Lipid complexes and liposomes of highly insoluble platinum complexes | |
JP2012207042A (ja) | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 | |
JP2018502870A (ja) | トラネキサム酸の多小胞リポソーム処方物 | |
BE1021939B1 (fr) | Composition pour des composes aminoalkylglucosaminide phosphate tamponnes et son utilisation. | |
PL183040B1 (pl) | Kompozycja farmaceutyczna nierozpuszczalnych w wodzie kamptotecyn | |
WO1989002265A1 (fr) | Emulsion grasse contenant un medicament, du type prepare immediatement avant l'utilisation, et procede de preparation d'une telle emulsion grasse contenant un medicament | |
JP6230538B2 (ja) | 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法 | |
CN113456591B (zh) | 糖基聚醚类化合物脂质体及其制备方法和药物 | |
EP0241376A1 (fr) | Nouveaux liposomes à base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant | |
US20020058060A1 (en) | Liposome for incorporating large amounts of hydrophobic substances | |
EP2197492A1 (fr) | Nouvelles compositions a base de taxoides | |
WO2013176223A1 (fr) | Composition pharmaceutique pour traiter une maladie inflammatoire | |
JP2003516348A (ja) | がん治療のための細胞増殖抑制剤及び電子受容体を含有する医薬製剤 | |
WO2013026989A2 (fr) | Liposome comprenant au moins un derive de cholesterol | |
AU2013203682B2 (en) | Liposome comprising at least one cholesterol derivative | |
CN112773776B (zh) | 一种载药纳米粒体系 | |
JP4694776B2 (ja) | 微小粒子組成物又はリポソーム製剤 | |
JP7186385B2 (ja) | 疾患部位特異的リポソーム製剤 | |
Anderson et al. | Liposomal, Ring-Opened Camptothecins with Prolonged, Site-Specific Delivery of Active Drug to Solid Tumors | |
JP2009502764A (ja) | 担体と有効成分の分子間結合錯体 | |
JPH0469146B2 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12758576 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2845691 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014526535 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/002228 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014004163 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14240990 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112014004163 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140221 |